OncRef

Clinical Trial: NCT03249870

Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:Versailles Hospital
Information Provided By:Versailles Hospital
Last Update Posted:2026-06-22

Study Overview

Brief Summary

The aim of the present EWALL-INO study is to confirm very promising results obtained with a combination of INO and mild chemotherapy in older de novo CD22+ B-ALL patients. For that purpose, safety and efficacy of a weekly INO administration combined to mild-intensity chemotherapy will be evaluated in a cohort of patients aged more than 55 years with newly diagnosed previously untreated Ph-negative (CD22+) BCP-ALL. Conversely to the MDACC miniHCVD-INO study and in order to lower the overall toxicity of the combination, INO will be given as part of the remission induction treatment phase during the first 2 treatment cycles only, in combination with corticosteroid, vincristine, cyclophosphamide and intrathecal prophylaxis only; then, all responding patients will received standard INO-free chemotherapy as consolidation and maintenance.

Official Title

A Phase 2 Study of Inotuzumab Ozogamicin (INO) Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor Acute Lymphoblastic Leukemia

Conditions

Acute Lymphoblastic Leukemia (ALL) - Philadelphia Chromosome (Ph)-Negative CD22+ B-cell Precursor (BCP)

Intervention / Treatment

  • Drug: Inotuzumab ozogamicin (INO)

Other Study ID Numbers

  • P16/11- EWALL INO
  • 2016-004942-27
  • 2016

Start Date (Actual)

2017-12-28

Primary Completion Date (Actual)

2024-10-17

Study Completion Date (Actual)

2024-10-17

Enrollment (Actual)

131

Study Type

Interventional

Phase

Phase 2